Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Sees Large Increase in Short Interest

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) was the target of a significant increase in short interest during the month of July. As of July 31st, there was short interest totaling 177,544 shares, an increase of 571.2% from the July 15th total of 26,452 shares. Approximately 1.2% of the shares of the company are short sold. Based on an average trading volume of 466,302 shares, the short-interest ratio is currently 0.4 days.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of ENLV. Virtu Financial LLC acquired a new position in Enlivex Therapeutics during the 4th quarter worth approximately $33,000. Invesco Ltd. acquired a new position in shares of Enlivex Therapeutics in the fourth quarter valued at $43,000. XTX Topco Ltd lifted its position in Enlivex Therapeutics by 44.8% during the fourth quarter. XTX Topco Ltd now owns 61,800 shares of the company’s stock worth $43,000 after acquiring an additional 19,132 shares during the last quarter. Jane Street Group LLC boosted its stake in Enlivex Therapeutics by 244.1% in the 4th quarter. Jane Street Group LLC now owns 74,082 shares of the company’s stock valued at $52,000 after purchasing an additional 52,553 shares during the period. Finally, Susquehanna International Group LLP bought a new stake in shares of Enlivex Therapeutics in the third quarter valued at about $57,000. 1.02% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Wall Street Zen raised Enlivex Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, April 25th. Zacks Research raised shares of Enlivex Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 21st. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Enlivex Therapeutics in a research note on Friday, June 26th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $247.50.

Enlivex Therapeutics Stock Down 5.7%

Enlivex Therapeutics stock traded down $0.11 during mid-day trading on Wednesday, hitting $1.81. 382,118 shares of the company’s stock were exchanged, compared to its average volume of 83,315. Enlivex Therapeutics has a fifty-two week low of $1.72 and a fifty-two week high of $31.50. The firm has a market capitalization of $30.47 million, a P/E ratio of -0.22 and a beta of 1.60. The company’s 50 day simple moving average is $6.69 and its 200-day simple moving average is $11.78.

About Enlivex Therapeutics

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.